Biliary Tract Neoplasm
4
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
5 treatments under study, led by Oxaliplatin Irinotecan S1
Research Leaders
5 sponsors active, led by Hallym University Medical Center
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 4 trials
100.0%
+13.4% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (4)
Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer
MRCP Diagnoses EHCC Better When Combined DWI
Gemcitabine and S-1 for Advanced Biliary Tract Cancer
Pre-habilitation to Improve Outcomes in Patients Undergoing Liver Resection for Cancer
Research Network
Common Treatments
- Oxaliplatin Irinotecan S11
- Gemcitabine And S11
- Whey Protein And Dietary Supplements1
- Prehab Exercise1
- 3t Mri1
Active Sponsors
- Hallym University Medical Center2
- Jeil Pharmaceutical Co., Ltd.2
- First Hospital of China Medical University1
- McGill University Health Centre/Research Institute of the McGill University Health Centre1
- China Medical University, China1
Top Investigators
Hallym University Medical Center
McGill University Health Centre/Research Institute of the McGill University Health Centre
First Hospital of China Medical University
Related Conditions
- Liver Neoplasm1
- Cholangiocarcinoma1
- Colorectal Neoplasm1